HIV and Fat Accumulation
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/6/2019 |
| Start Date: | May 2010 |
| End Date: | June 2011 |
Metabolic Abnormalities, Telmisartan and HIV Infection
This is a research study to see whether fat accumulation either under the skin or in the
body's organs, for example, the liver, improves in men and women who take a drug called
telmisartan. The investigators will be looking at how the amount of fat in the body changes
when HIV-positive persons on effective anti-HIV therapy take telmisartan. The investigators
will be using a CT scan to make this comparison. Telmisartan is not an HIV medication. It is
a medication used to treat blood pressure, but has been shown to decrease fat in the organs
in people both with and without high blood pressure. The study involves 8 visits over a
period of about 24 weeks.
body's organs, for example, the liver, improves in men and women who take a drug called
telmisartan. The investigators will be looking at how the amount of fat in the body changes
when HIV-positive persons on effective anti-HIV therapy take telmisartan. The investigators
will be using a CT scan to make this comparison. Telmisartan is not an HIV medication. It is
a medication used to treat blood pressure, but has been shown to decrease fat in the organs
in people both with and without high blood pressure. The study involves 8 visits over a
period of about 24 weeks.
Inclusion Criteria:
- HIV positive men and women 18 years and older
- HIV-1 infection as documented by ELISA and confirmed by Western blot or plasma HIV-1
RNA >2000 on two occasions
- Documented central fat accumulation
- HIV RNA documented to be less than 50 copies/mL at screening and undetectable by assay
of choice for at least 12 weeks prior to entry
- Current antiretroviral therapy with a suppressive, highly active antiretroviral
regimen.
- Systolic BP >115mmHg.
- Ability and willingness to provide informed consent
Exclusion Criteria:
- Pregnancy (current or within the last 6 months) or nursing
- Uncontrolled hypertension
- Prohibited concomitant medications
- Subjects with untreated hyperlipidemia must be willing to abstain from initiating
therapy for the 24 week duration fo the study.
- Subjects undergoing treatment for diabetes with oral hypoglycemic agents must be
willing to remain on their current dose of insulin sensitizing agents for the duration
of the study.
- Known, untreated renal artery stenosis
- Unstable coronary artery disease/angina or decompensated congestive heart failure.
- Any history of intolerance to any member of the angiotensin receptor blocker class of
agents.
- Need for ongoing potassium supplementation.
- Screening laboratory values as follows ANC (absolute neutrophil count) <750 cells/mm3
Hemoglobin <10 gm/dL ClCr (creatinine clearance)< 30 ml/min (estimated by
Cockcroft-Gault equation) AST (aspartate aminotransferase) or ALT (alanine
aminotransferase) > 3 x ULN (upper limit of normal)
We found this trial at
1
site
Click here to add this to my saved trials
